At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Zydeligdrug
Likely dose
Zydelig 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
In Brief
A Phase 2 clinical trial evaluating Zydelig for Non Hodgkin Lymphoma and 8 related conditions. Completed, enrolled 17 participants across 3 sites.
Detailed Summary
This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartOct 2017
Primary CompletionJun 2023
Study CompletionSep 2024
TodayJul 2026
First PostedApr 28, 2017
Enrollment StartOct 23, 2017
Primary CompletionJun 15, 2023
Study CompletionSep 29, 2024
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.2 years ago
Interventions
Zydeligdrug
Zydelig given at 150mg continuously in 28-day cycles